What do systematic reviews say?

Selexipag vs placebo

Selexipag showed no clear difference in improvement in WHO functional class compared with placebo (moderate certainty).

• Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
  OR 1.61 [0.17, 15.63]
  1 study · 43 participants
  Moderate

Selexipag vs placebo

• Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1199 participants
  High

Selexipag vs placebo

• Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1199 participants
  Moderate

Selexipag vs placebo

• Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 43 participants
  Moderate

Selexipag vs placebo

• Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 43 participants
  Moderate

Selexipag vs placebo

• Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 43 participants
  Moderate

Selexipag vs placebo

• Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 43 participants
  Moderate

Selexipag vs placebo

• Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 43 participants
  Moderate

Selexipag vs placebo

• Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1199 participants
  High

Prostacyclin vs control

• Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  13 studies · 2283 participants
  Low

Prostacyclin vs control

Prostacyclin probably leads to lower mortality compared with control (moderate certainty).

• Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
  OR 0.6 [0.38, 0.94]
  15 studies · 2554 participants
  Moderate

Prostacyclin vs control

• Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 1132 participants
  Low

Prostacyclin vs control

• Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 658 participants
  Moderate

Prostacyclin vs control

• Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 868 participants
  Low

Prostacyclin vs control

• Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 1060 participants
  Moderate

Prostacyclin vs control

• Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 1521 participants
  Low

Prostacyclin vs control

• Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 271 participants
  Moderate

LABA/LAMA vs placebo

Once‐daily LABA/LAMA in a combined inhaler showed no clear difference in all‐cause mortality (3‐week to 1‐year compared with placebo (low certainty).

• Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus placebo for… 2019 · Cochrane Headline outcomes only
  OR 1.88 [0.81, 4.36]
  18 studies · 8752 participants
  Low

LABA/LAMA vs placebo

Once‐daily LABA/LAMA in a combined inhaler showed no clear difference in serious adverse events (3‐week to 1‐year compared with placebo (high certainty).

• Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus placebo for… 2019 · Cochrane Headline outcomes only
  OR 1.06 [0.88, 1.28]
  22 studies · 10536 participants
  High

LABA/LAMA vs placebo

Once‐daily LABA/LAMA in a combined inhaler probably leads to lower acute exacerbations of COPD (4‐week to 24‐week compared with placebo (moderate certainty).

• Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus placebo for… 2019 · Cochrane Headline outcomes only
  OR 0.53 [0.36, 0.78]
  3 studies · 1127 participants
  Moderate